Aczone Gel 5%, made by QLT Inc., is approved to treat acne vulgaris that tarnishes lives of many teens and adults. It is estimated that some people - especially women - have acne into their 40s and 50s.

The water-based active ingredient of new acne gel treatment is dapsone. It is the only acne treatment to use dapsone in a topical formulation, states a QLT news release.

-------- ARTICLE CONTINUES BELOW --------

Find out how you can treat acne – naturally and easy from home.


Clinically proven acne treatment to address the underlying cause of acne. Results: lasting clear skin, no more breakouts. Treatment involves daily home procedures and certain lifestyle changes. No more acne guaranteed or money back.


Instant download, 124 pages of exclusive new science-based information and step-by-step natural acne treatment guides.

-------- CONTINUE READING ARTICLE --------


Aczone was tested in two clinical trials with more than 3,000 acne patients aged 12 and older. It was compared with a similar gel without dapsone.

Aczone fared better than the comparison gel. After three months, Aczone reduced more pimples.

Women tended to have more success and fewer pimples with Aczone than men.

The most commonly reported side effects in the clinical trials were oiliness/peeling, dryness, and skin redness. Side effects were similar with both gels.

Patients will need to be screened to see if they are predisposed to have a type of potentially severe anemia called hemolytic anemia due to a lack of the G6PD enzyme.

A deficiency of this enzyme may result in the destruction of oxygen-carrying red blood cells when a person is exposed to certain medications or chemicals, has certain viral or bacterial infections, and/or inhales the pollen of, or eats, fava beans.

Those who have the rare enzyme deficiency will need to have regular blood counts done, states the release.

According to QLT, the deficiency was present in 1.4% of the trials' patients. It's more common in some groups, reportedly affecting 10% to 14% of black men, states the release.

QLT has agreed to do a postapproval study in 50 patients with G6PD deficiency. Depending on the results of the study, the company may submit an application to the FDA to re-evaluate the gel's label.

The active ingredient in Aczone is also used to treat leprosy. However, it's taken as a pill for this condition. 

 Other news